HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1160-1165

  Rakovitch, E ^a,b   Nofech Mozes, S ^b   Hanna, W ^b   Narod, S ^b   Thiruchelvam, D ^b   Saskin, R ^b   Spayne, J ^a,b   Taylor, C ^b   Paszat, L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

biomarkers; breast conserving surgery; DCIS; recurrence

Indexed keywords

CALGRANULIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; PSORIASIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84858285120     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.41     Document Type: Article

References (18)

1. Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R, Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R (2004) The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 100: 2317-2327 (Pubitemid 38657878)
2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer: New York, NY
3. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH,UrbanN, Geller BM (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. JNCI Cancer Spectrum 94: 1546-1554 (Pubitemid 35277278)
4. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16: 441-452 (Pubitemid 28135585)
5. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180 (Pubitemid 24308077)
6. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, UK Coordinating Committee on Cancer Research, Ductal Carcinoma in situ Working Party, DCIS trialists in the UK AaNZ (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362: 95-102 (Pubitemid 36831018)
7. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, van Dongen JA (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355: 528-533 (Pubitemid 30088672)
8. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102: 627-637
9. Latta EK, Tjan S, Parkes RK, O0Malley FP, Latta EK, Tjan S, Parkes RK, O'Malley FP (2002) The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 15: 1318-1325 (Pubitemid 35463000)
10. Lauzier S, Levesque P, Drolet M, Coyle D, Brisson J, Masse B, Robidoux A, Robert J, Maunsell E (2011) Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer. J Clin Oncol 29: 4007-4013
11. Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E (1998) Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol 16: 2625-2631, (published erratum appears in Feb 1999 J Clin Oncol; 17(2): 740) (Pubitemid 28363025)
12. Paszat LF, Vallis KA, Benk VM, Groome PA, Mackillop WJ, Wielgosz A (2007) A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. Radiother Oncol 82: 294-300 (Pubitemid 46341476)
13. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE, Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE (2003) Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 39: 622-630 (Pubitemid 36287374)
14. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M, Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M, South Sweden Breast Cancer Group (2001) Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37: 1514-1522 (Pubitemid 32744682)
15. Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger AM (2003) Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res 23: 2043-2051 (Pubitemid 36897163)
16. Sikand K, Lee AH, Pinder SE, Elston CW, Ellis IO, Sikand K, Lee AHS, Pinder SE, Elston CW, Ellis IO (2005) Sections of the nipple and quadrants in mastectomy specimens for carcinoma are of limited value. J Clin Pathol 58: 543-545 (Pubitemid 40646878)
17. Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ, Gamagami P, Waisman JR (1998) Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 16: 1367-1373 (Pubitemid 28175753)
18. Solin LJ, Fourquet A, McCormick B, Haffty B, Recht A, Schultz DJ, Barrett W, Fowble BL, Kuske R, Taylor M (1994) Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast. Int J Radiat Oncol Biol Phys 30: 3-9 (Pubitemid 24291107)